7.4mg Wegovy: Is This a Real Dose, and What Comes Next?

Why does 7.4mg Wegovy keep appearing, where does the number come from?

The short answer is search confusion. When Novo Nordisk and the MHRA announced the new higher-dose semaglutide pen, news coverage and forums rounded or garbled the figure in various ways. The actual approval was for 7.2mg, announced on 14 April 2026. Typing 7.4 into a search bar lands people on questions that should really be about 7.2mg, which is a genuine and significant development.

The existing Wegovy injection schedule runs 0.25mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg, each step taken roughly four weeks apart under prescriber guidance. For most patients, 2.4mg has been the endpoint, and anyone curious about the step just below it can read more about Wegovy 3.4 and where it sits in the dose progression. There is no 7.3mg, no 7.4mg, no 7.5mg in the licensed range. If you see a seller listing any of those numbers, that is a red flag worth taking seriously.

A quick check takes under a minute: look up any UK pharmacy on the GPhC pharmacy register before buying anything. A legitimate registered pharmacy will be listed; one that isn't shouldn't be dispensing prescription medicines at all.

What exactly was approved at 7.2mg, and who does the clinical trial evidence apply to?

The MHRA approved the dedicated 7.2mg Wegovy pen as a single pre-set weekly injection on 14 April 2026. It carries an auto-dosing mechanism, a built-in covered needle that locks after use, and requires no reconstitution or dialling. The licence covers adults with a BMI of 30 or above, the lower 27–29.9 range with a weight-related condition does not extend to this dose. Starting dose remains 0.25mg, working up through the standard schedule; 7.2mg is the maximum any prescriber can reach.

Trial evidence reported average weight loss of around 20.7% over 72 weeks at this dose. That puts it in territory that was previously only seen with tirzepatide's higher strengths. The STEP 1 trial in the New England Journal of Medicine established 2.4mg at around 15% average weight reduction over 68 weeks; 7.2mg builds meaningfully on that figure, though individual results vary and no outcome can be guaranteed.

For the broader picture of how semaglutide works as a GLP-1 receptor agonist, the science behind Wegovy is worth reading alongside this page.

How does the 7.2mg dose fit into private treatment, can you request it from the start?

No. Treatment always begins at 0.25mg regardless of the target maintenance dose, and each step is clinically reviewed before the next increase. That is not arbitrary, the escalation exists because starting at a high dose significantly increases gastrointestinal side effects. Nausea, loose stools, indigestion and fatigue are most pronounced in the first weeks of each new dose; moving up too quickly makes that worse for most people.

A prescriber decides whether 7.2mg is appropriate based on how someone tolerates lower doses, their weight trajectory, and other clinical factors. Specific dose availability for the new pen is confirmed at consultation, never assume a particular format is in stock. The general picture of what private Wegovy treatment involves, including cost context, is covered on the where to get Wegovy page.

If you are currently on 2.4mg through another provider and want to explore whether 7.2mg is something to discuss, what the second month of treatment looks like explains how dose reviews typically work. Transfer patients at nume provide evidence of their current dose before any increase is considered.

What should you actually do if you searched for 7.4mg Wegovy?

The most useful next step depends on where you are in your treatment journey. If you haven't started yet, the Wegovy overview sets out the full picture, licensing, eligibility, how the dose schedule works from the beginning. If you're already on treatment and wondering whether the higher dose might be relevant to you, that is a conversation for your prescriber, not a search result.

It is also worth knowing how Wegovy compares to the other weekly injection licensed for weight management. Semaglutide and tirzepatide work through different mechanisms; the weight loss treatments overview puts both in context without pushing you toward either. For any question about which medicine or dose applies to your specific situation, a clinical assessment is the only reliable answer. The MHRA's Yellow Card scheme is also available to report any suspected side effects or concerns about suspect sellers.

If you'd like a GPhC-registered prescriber to review your situation and advise on suitability, you can start your free consultation with nume today, same-day clinical review, plain packaging, and no subscription.